Intention to Treat Analysis
"Intention to Treat Analysis" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Strategy for the analysis of RANDOMIZED CONTROLLED TRIALS AS TOPIC that compares patients in the groups to which they were originally randomly assigned.
| Descriptor ID |
D057194
|
| MeSH Number(s) |
E05.318.760.250.500.365.500.250 N05.715.360.775.088.500.387.500.500 N06.850.520.450.250.250.365.500.500
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Intention to Treat Analysis".
Below are MeSH descriptors whose meaning is more specific than "Intention to Treat Analysis".
This graph shows the total number of publications written about "Intention to Treat Analysis" by people in this website by year, and whether "Intention to Treat Analysis" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2010 | 0 | 2 | 2 |
| 2011 | 0 | 2 | 2 |
| 2012 | 0 | 1 | 1 |
| 2015 | 0 | 1 | 1 |
| 2016 | 0 | 1 | 1 |
| 2017 | 0 | 3 | 3 |
| 2019 | 0 | 1 | 1 |
| 2020 | 0 | 1 | 1 |
| 2021 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Intention to Treat Analysis" by people in Profiles.
-
Edoxaban versus Vitamin K Antagonist for Atrial Fibrillation after TAVR. N Engl J Med. 2021 12 02; 385(23):2150-2160.
-
Portosystemic shunts versus endoscopic intervention with or without medical treatment for prevention of rebleeding in people with cirrhosis. Cochrane Database Syst Rev. 2020 10 22; 10:CD000553.
-
Standardized classification and framework for reporting, interpreting, and analysing medication non-adherence in cardiovascular clinical trials: a consensus report from the Non-adherence Academic Research Consortium (NARC). Eur Heart J. 2019 07 01; 40(25):2070-2085.
-
Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism. N Engl J Med. 2018 Feb 15; 378(7):615-624.
-
Tumor Microvessel Density as a Potential Predictive Marker for Bevacizumab Benefit: GOG-0218 Biomarker Analyses. J Natl Cancer Inst. 2017 11 01; 109(11).
-
Preventing Alcohol and Tobacco Exposed Pregnancies: CHOICES Plus in Primary Care. Am J Prev Med. 2017 Jul; 53(1):85-95.
-
Weekly vs. Every-3-Week Paclitaxel and Carboplatin for Ovarian Cancer. N Engl J Med. 2016 Feb 25; 374(8):738-48.
-
Effects of red-cell storage duration on patients undergoing cardiac surgery. N Engl J Med. 2015 Apr 09; 372(15):1419-29.
-
Apixaban for extended treatment of venous thromboembolism. N Engl J Med. 2013 02 21; 368(8):699-708.
-
A phase II clinical trial of pegylated liposomal doxorubicin and carboplatin plus bevacizumab in patients with platinum-sensitive recurrent ovarian, fallopian tube, or primary peritoneal cancer. Gynecol Oncol. 2012 Sep; 126(3):369-74.